When A REMS Is Not Enough: BMS Needs More Safety Data For Belatacept
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's "complete response" letter for kidney transplant drug does not require that Bristol-Myers Squibb do additional clinical trials, but firm must provide updates from ongoing study before approval.